Article Details

J&J spends $100M to join Roche and Regeneron in bispecific blood cancer race - Fierce Biotech

Retrieved on: 2021-10-04 12:00:00

Tags for this article:

Click the tags to see associated articles and topics

J&J spends $100M to join Roche and Regeneron in bispecific blood cancer race - Fierce Biotech. View article details on hiswai:

Excerpt

The race to use bispecifics to treat blood cancers is heating up, with Johnson & Johnson paying $100 million upfront to challenge Regeneron and Roche in a ...

Article found on: www.fiercebiotech.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up